Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.

By Sally E. Wenzel, D. Wilbraham, R. Fuller, E. B. Getz, M. Longphre. The Lancet, 2007

611 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

T-helper type 2-driven inflammation defines major subphenotypes of asthma. (2009, background): “Second, blockade of IL-13 and related Th2 cytokines is under active clinical development as a therapeutic strategy in asthma (5).”
Alternative activation of macrophages: mechanism and functions. (2010, background): “In a well-controlled phase 2a trial (Wenzel et al., 2007), recombinant human pitrakinra showed promising results in ameliorating late-phase asthmatic response to allergen challenge in patients, by aerosol and subcutaneous routes.”
Treatment strategies for allergy and asthma (2008, background): “Subcutaneous or inhaled pitrakinra, a mutant IL-4 protein that inhibits the binding of IL-4 and IL-13 to IL-4Rα complexes, has recently shown efficacy in the treatment of allergen-induced asthm”
The cytokine network in asthma and chronic obstructive pulmonary disease. (2008, background): “Pitrakinra, a mutated form of IL-4 that blocks the binding of IL-4 and IL-13 to IL-4Rα, reduces the late response to inhaled allergen in asthmatic patients after either inhaled or subcutaneous administration (15).”